Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, June 21, 2022
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
Sun, June 19, 2022
[ Sun, Jun 19th 2022
] - WOPRAI
Fri, June 17, 2022
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
[ Fri, Jun 17th 2022
] - WOPRAI
Kostas Biliouris Initiated (VERV) at Buy and Held Target at $48 on, Jun 17th, 2022
Kostas Biliouris of BMO Capital, Initiated "Verve Therapeutics, Inc." (VERV) at Buy and Held Target at $48 on, Jun 17th, 2022.
Kostas has made no other calls on VERV in the last 4 months.
There is 1 other peer that has a rating on VERV. Out of the 1 peers that are also analyzing VERV, 0 agree with Kostas's Rating of Hold.
This is the rating of the analyst that currently disagrees with Kostas
- Luca Issi of "RBC Capital" Initiated at Buy and Held Target at $42 on, Friday, February 18th, 2022
